ALGS (Aligos Therapeutics) Policyholder Funds

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALGS Aligos Therapeutics Inc ALGS
45 GF Score
Price $7.27
GF Value $34.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Aligos Therapeutics Policyholder Funds?

Policyholder Funds only applies to insurance companies.

ALGS
45GF Score
Aligos Therapeutics Inc ALGS
Policyholder Funds is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued. The current stock price of $7.27 is trading 78.8% below its estimated GF Value™ of $34.33. GuruFocus considers Aligos Therapeutics to be Possible Value Trap.

Key valuation signals for ALGS:

  • Policyholder Funds:
  • GF Value™: $34.33 vs. price of $7.27 (78.8% below fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
45GF Score

Get the complete analysis for ALGS

Policyholder Funds is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.27
Price
$34.33
GF Value